Abstract
Effective strategies for preventing human cancer resulting from exposure to chemical carcinogens of environmental, occupational or life-style sources, require the identification of the carcinogens to which people are exposed and the evaluation of the degree of exposure. The use of biological markers to detect such exposure and the early events in the process of carcinogenesis has increased greatly in recent years and their use is expected to be of help for the assessment of future disease risk.1–3
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Perera, F.P. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J. Natl. Cancer Inst., 88: 496–509, 1996.
La, D.K. and Swenberg, J.A. DNA adducts: biological markers of exposure and potential applications to risk assessment. Mutat. Res., 365: 129–146, 1996.
Dale, C.M. and Garner, R.C. Measurement of DNA adducts in humans after complex mixture exposure. Food Chem. Toxicol., 34: 905–919, 1996.
Miller, E.C. and Miller, J.A. Mechanisms of chemical carcinogenesis. Cancer, 47: 1055–1064, 1981.
Wogan, G.N. Molecular epidemiology in cancer risk assessment and prevention: Recent progress and avenues for future research. Environ. Health Perspect., 98: 167–178, 1992.
Skipper, P.L. and Tannenbaum, S.R. Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis, 11: 507–518, 1990.
Harris, C.C. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res., 51: 5023s - 5044s, 1991.
Swenberg, J.A., Fedtke, N., Fennell, T.R., and Walker, V.E. Relationships between carcinogen exposure, DNA adducts and carcinogenesis. In: D.B. Clayson, I.C. Munro, P. Shubik, and J.A. Swenberg (eds.), Progress in Predictive Toxicology, pp. 161–184, Amsterdam: Elsevier. 1990.
Brookes, P. and Lawley, P.D. Evidence for the binding of polynuclear aromatic hydrocarbons to the nucleic acids of mouse skin: relation between carcinogenic power of the hydrocarbons and their binding to deoxyribonucleic acid. Nature, 202: 781–784, 1964.
Lutz, W.K. Quantitative evaluation of DNA binding data for risk estimation and for classification of direct and indirect carcinogens. J. Cancer Res. Clin. Oncol., 112: 85–91, 1986.
Poirier, M.C. The use of carcinogen-DNA adduct antisera for quantitation and localization of genomic damage in animal models and the human population. Environ. Mutagen., 6: 879–887, 1984.
Wogan, G.N. and Gorelick, N.J. Chemical and biochemical dosimetry of exposure to genotoxic chemicals. Environ. Health Perspect., 62: 5–18, 1985.
Nesnow, S., Ross, J.A., Mass, M.J., and Stoner, G.D. Mechanistic relationships between DNA adducts, oncogene mutations, and lung tumorigenesis in strain A mice. Exp. Lung Res., 24: 395–405, 1998.
Denissenko, M.F., Pao, A., Tang, M., and Pfeifer, G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science, 274: 430–432, 1996.
Gupta, R.C. Nonrandom binding of the carcinogen N-hydroxy-2-acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. Proc. Natl. Acad. Sci. USA, 81: 6943–6947, 1984.
Dipple, A. DNA adducts of chemical carcinogens. Carcinogenesis, 16: 437–441, 1995.
Loveless, A. Possibile relevance of O-6 alkylation of deoxyguanosine to the mutagenicity and carcinogenicity of nitrosamines and nitrosamides. Nature, 223: 206–207, 1969.
Singer, B. N-nitroso alkylating agents: formation and persistence of alkyl derivatives in mammalian nucleic acids as contributing factors in carcinogenesis. J. Natl. Cancer Inst., 62: 1329–1339, 1979.
Saffhill, R., Margison, G.P., and O’Connor, P.J. Mechanisms of carcinogenesis induced by alkylating agents. Biochim. Biophys. Acta, 823: 111–145, 1985.
Jerina, D.M., Chadha, A., Cheh, A.M., Schurdak, M.E., Wood, A.W., and Sayer, J.M. Covalent binding of bay-region diol epoxides to nucleic acids. Adv. Exp. Med. Biol., 283: 533–553, 1991.
Jernstrom, B. and Graslund, A. Covalent binding of benzo[a]pyrene 7,8-dihydrodiol 9,10-epoxides to DNA: molecular structures, induced mutations, and biological consequences. Biophys. Chem., 49: 185–199, 1994.
Humphreys, W.G., Kadlubar, F.F., and Guengerich, F.P. Mechanism of C8 alkylation of guanine residues by activated arylamines: evidence for initial adduct formation at the N7 position. Proc. Natl. Acad. Sci. USA, 89: 8278–8282, 1992.
Essigmann, J.M., Croy, R.G., Nadzan, A.M., Busby, W.F.,Jr., Reinhold, V.N., Buchi, G., and Wogan, G.N. Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc. Natl. Acad. Sci. USA, 74: 1870–1874, 1977.
Croy, R.G., Essigmann, J.M., Reinhold, V.N., and Wogan, G.N. Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver. Proc. Natl. Acad. Sci. USA, 75: 1745–1749, 1978.
Phillips, D.H., Hemminki, K., Alhonen, A., Hewer, A., and Grover, P.L. Monitoring occupational exposure to carcinogens: detection by 32P-postlabelling of aromatic DNA adducts in white blood cells of iron foundry workers. Mutat. Res., 204: 531–541, 1988.
Cuzick, J., Routledge, M.N., Jenkins, D., and Garner, R.C. DNA adducts in different tissues of smokers and non-smokers. Int. J. Cancer, 45: 673–678, 1990.
Talaska, G., Schamer, M., Skipper, P, Tannenbaum, S., Caporaso, N., Unruh, L., Kadlubar, PF., Bartsch, H., Malaveille, C., and Vineis, P Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers: association with smoking, hemoglobin adducts, and urinary mutagenicity. Cancer Epidemiol. Biomarkers. Prey., 1: 61–66, 1991.
Hsu, T.M., Zhang, Y.J., and Santella, R.M. Immunoperoxidase quantitation of 4-aminobiphenyl-and polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral and urothelial cells of smokers and nonsmokers. Cancer Epidemiol. Biomarkers. Prev., 6: 193–199, 1997.
Talaska, G., al-Juburi, A.Z., and Kadlubar, F.F. Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc. Natl. Acad. Sci. USA, 88: 5350–5354, 1991.
Arnould, J.P, Verhoest, P., Bach, V., Libert, J.P., and Belegaud, J. Detection of benzo[a]pyrene-DNA adducts in human placenta and umbilical cord blood. Hum. Exp. Toxicol., 16: 716–721, 1997.
Shuker, D.E.G. and Farmer, P.B. Relevance of urinary DNA adducts as markers of carcinogen exposure. Chem. Res. Toxicol., 5: 450–460, 1992.
Groopman, J.D., Donahue, P.R., Zhu, J.Q., Chen, J.S., and Wogan, G.N. Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc. Natl. Acad. Sci. USA, 82: 6492–6496, 1985.
Gupta, R.C., Reddy, M.V., and Randerath, K. 32P-postlabeling analysis of non-radioactive aromatic carcinogen—DNA adducts. Carcinogenesis, 3: 1081–1092, 1982.
Gupta, R.C. 32P-postlabelling analysis of bulky aromatic adducts. IARC Sci. Publ., 124: 11–23, 1993.
Beach, A.C. and Gupta, R.C. Human biomonitoring and the 32P-postlabeling assay. Carcinogenesis, 13: 1053–1074, 1992.
Reddy, M.V. and Randerath, K. Nuclease Pl-mediated enhancement of sensitivity of 32Ppostlabeling test for structurally diverse DNA adducts. Carcinogenesis, 7: 1543–1551, 1986.
Levy, G.N. and Weber, W.W. High-performance liquid chromatographic analysis of 32P-postlabeled DNA-aromatic carcinogen adducts. Anal. Biochem., 174: 381–392, 1988.
Poirier, M.C. Human exposure monitoring, dosimetry, and cancer risk assessment: the use of antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA. Drug Metab. Rev., 26: 87–109, 1994.
Strickland, P.T. and Boyle, J.M. Immunoassay of carcinogen-modified DNA. Prog. Nucleic Acid Res. Mol. Biol., 31: 1–58, 1984.
Kriek, E., Den Engelse, L., Scherer, E., and Westra, J.G. Formation of DNA modifications by chemical carcinogens. Identification, localization, and quantification. Biochim. Biophys. Acta, 738: 181–201, 1984.
Harris, C.C., Yolken, R.H., and Hsu, I-C. Enzyme immunoassays: applications in cancer research. In: H. Busch and L.C. Yeoman (eds.), Methods in Cancer Research, Vol. XX, pp. 213–243, New York: Academic Press. 1982.
Hsu, I.C., Poirier, M.C., Yuspa, S.H., Grunberger, D., Weinstein, I.B., Yolken, R.H., and Harris, C.C. Measurement of benzo(a)pyrene-DNA adducts by enzyme immunoassays and radioimmunoassay. Cancer Res., 41: 1091–1095, 1981.
King, M.M., Cuzick, J., Jenkins, D., Routledge, M.N., and Garner, R.C. Immunoaffinity concentration of human lung DNA adducts using an anti-benzo[a]pyrene-diol-epoxide-DNA antibody. Analysis by 32P-postlabelling or ELISA. Mutat. Res., 292: 113–122, 1993.
Airoldi, L., Magagnotti, C., Chiappetta, L., Bonfanti, M., Pastorelli, R., and Fanelli, R. Simultaneous immunoaffinity purification of 06-methyl, 06-ethyl-, 06-propyl-and, 06-butylguanine and their analysis by gas chromatography/mass spectrometry. Carcinogenesis, 16: 2247–2250, 1995.
Pastorelli, R., Guanci, M., Cerri, A., Negri, E., La Vecchia, C., Fumagalli, F, Mezzetti, M., Cappelli, R., Panigalli, T., Fanelli, R., and Airoldi, L. Impact of inherited polymorphisms in glutathione S-transferase Ml, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide. Cancer Epidemiol. Biomarkers. Prev., 7: 703–709, 1998.
Vahakangas, K., Haugen, A., and Harris, C.C. An applied synchronous fluorescence spectrophotometric assay to study benzo[a]pyrene-diolepoxide-DNA adducts. Carcinogenesis, 6: 1109–1115, 1985.
Autrup, H., Bradley, K.A., Shamsuddin, A.K.M., Wakhisi, J., and Wasunna, A. Detection of putative adduct with fluorescence characteristics identical to 2,3-dihydro-2-(7’-guanyl)-3-hydroxyaflatoxin B1 in human urine collected in Murang’a district, Kenya. Carcinogenesis, 4: 1193–1195, 1983.
Autrup, H., Wakhisi, J., Vahakangas, K., Wasunna, A., and Harris, C.C. Detection of 8,9-dihydro-(7’guanyl)-9-hydroxyaflatoxin B1 in human urine. Environ. Health Perspect., 62: 105–108, 1985.
Sanders, M.J., Cooper, R.S., Jankowiak, R., Small, G.J., Heisig, V., and Jeffrey, A.M. Identification of polycyclic aromatic hydrocarbon metabolites and DNA adducts in mixtures using fluorescence line narrowing spectrometry. Anal. Chem., 58: 816–820, 1986.
Strickland, P.T., Routledge, M.N., and Dipple, A. Methodologies for measuring carcinogen adducts in humans. Cancer Epidemiol. Biomarkers Prev., 2: 607–619, 1993.
Farmer, P.B., Bailey, E., Naylor, S., Anderson, D., Brooks, A., Cushnir, J., Lamb, J.H., Sepai, O., and Tang, Y.S. Identification of endogenous electrophiles by means of mass spectrometric determination of protein and DNA adducts. Environ. Health Perspect., 99: 19–24, 1993.
Lin, D., Lay, J.O.,Jr., Bryant, M.S., Malaveille, C., Friesen, M., Bartsch, H., Lang, N.P., and Kadlubar, F.F. Analysis of 4-aminobiphenyl-DNA adducts in human urinary bladder and lung by alkaline hydrolysis and negative ion gas chromatography-mass spectrometry. Environ. Health Perspect., 102 Suppl 6: 11–16, 1994.
Friesen, M.D., Kaderlik, K., Lin, D., Garren, L., Bartsch, H., Lang, N.P., and Kadlubar, F.F. Analysis of DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rat and human tissues by alkaline hydrolysis and gas chromatography/electron capture mass spectrometry: Validation by comparison with 32P-postlabeling. Chem. Res. Toxicol., 7: 733–739, 1994.
Kambouris, S.J., Chaudhary, A.K., and Blair, I.A. Liquid chromatography/electrospray ionization tandem mass spectroscopy (LC/ESI MS/MS) analysis of 1,2-epoxybutene adducts of purine deoxynucleosides. Toxicology, 113: 331–335, 1996.
Tang, D., Santella, R.M., Blackwood, A.M., Young, T.-L., Mayer, J., Jaretzki, A., Grantham, S., Tsai, W-Y., and Perera, F.P. A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol. Biomarkers Prey., 4: 341–346, 1995.
Peluso, M., Airoldi, L., Armelle, M., Martone, T., Coda, R., Malaveille, C., Giacomelli, G., Terrone, C., Casetta, G., and Vineis, R White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol. Biomarkers Prey., 7: 341–346, 1998.
Ross, R.K., Yuan, J.-M., Yu, M.C., Wogan, G.N., Qian, G.-S., Tu, J.-T., Groopman, J.D., Gao, Y.-T., and Henderson, B.E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339: 943–946, 1992.
Qian, G.-S., Ross, R.K., Yu, M.C., Yuan, J.-M., GaoY.-T., Henderson, B.E., Wogan, G.N., and Groopman, J.D. A follow-up study of urinary markers of afiatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol. Biomarkers Prey., 3: 3–10, 1994.
Binkova, B., Topinka, J., Mrackova, G., Gajdosova, D., Vidova, R, Stavkova, Z., Pilcik, RV., Rimar, V., Dobias, L., Farmer, P.B., and Sram, R.J. Coke oven workers study: the effect of exposure and GSTM1 and NAT2 genotypes on DNA adduct levels in white blood cells and lymphocytes as determined by 32P-postlabelling. Mutat. Res., 416: 67–84, 1998.
Peluso, M., Merlo, E, Munnia, A., Valerio, E, Perrotta, A., Puntoni, R., and Parodi, S. 32P-postlabeling detection of aromatic adducts in the white blood cell DNA of nonsmoking police officers. Cancer Epidemiol. Biomarkers Prey., 7: 3–11, 1998.
Van Schooten, FJ., Godschalk, R.W.L., Breedijk, A., Maas, L.M., Kriek, E., Sakai, H., Wigbout, G., Baas, R, Van’tVeer, L., and van Zandwijk, N. 32P-postlabelling of aromatic DNA adducts in white blood cells and alveolar macrophages of smokers: saturation at high exposures. Mutat. Res., 378: 65–75, 1997.
Hemminki, K., Dickey, C., Karlsson, S., Bell, D., Hsu, Y., Tsai, W.-Y., Mooney, L.A., Savela, K., and Perera, F.P. Aromatic DNA adducts in foundry workers in relation to exposure, life style and CYP1A1 and glutathione transferase M1 genotype. Carcinogenesis, 18: 345–350, 1997.
Mooney, L.A., Bell, D.A., Santella, R.M., Van Bennekum, A.M., Ottman, R., Paik, M., Blaner, W.S., Lucier, G.W., Covey, L., Young, T.-L., Cooper, T.B., and Glassman, A.H. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis, 18: 503–509, 1997.
Rojas, M., Alexandrov, K., Cascorbi, I., Brockmöller, J., Likhachev, A., Pozharisski, K., Bouvier, G., Auburtin, G., Mayer, L., Kopp-Schneider, A., Roots, I., and Bartsch, H. High benzo[a]pyrene diolepoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1 *0/*0 genotypes. Pharmacogenetics, 8: 109–118, 1998.
Martone, T., Airoldi, L., Magagnotti, C., Coda, R., Randone, D., Malaveille, C., Avanzi, G., Merletti, E, Hautefeuille, A., and Vineis, P. 4-Aminobiphenyl-DNA adducts and p53 mutations in bladder cancer. Int. J. Cancer, 75: 512–516, 1998.
Culp, S.J., Roberts, D.W., Talaska, G., Lang, N.P., Fu, P.P., Lay, J.O.Jr., Teitel, C.H., Snawder, J.E., Von Tungeln, L.S., and Kadlubar, F.F. Immunochemical, 32P-postlabeling, and GC/MS detection of 4aminobiphenyl-DNA adducts in human peripheral lung in relation to metabolic activation pathways involving pulmonary N-oxidation, conjugation, and peroxidation. Mutat. Res., 378: 97–112, 1997.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Airoldi, L., Pastorelli, R., Magagnotti, C., Fanelli, R. (1999). Carcinogen-DNA Adducts as Tools in Risk Assessment. In: Zappia, V., Della Ragione, F., Barbarisi, A., Russo, G.L., Iacovo, R.D. (eds) Advances in Nutrition and Cancer 2. Advances in Experimental Medicine and Biology, vol 472. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3230-6_20
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3230-6_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-3331-7
Online ISBN: 978-1-4757-3230-6
eBook Packages: Springer Book Archive